Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

GlaxoSmithKline (NYSE: GSK), Vir Biotechnology (NASDAQ: VIR), and Eli Lilly (NYSE: LLY) recently reported positive results from a phase 2 study evaluating a combination of Lilly's bamlanivimab with Vir's and Glaxo's VIR-7831 in treating COVID-19. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli examine those results and discuss which of the three stocks is likely to be the biggest winner going forward.